Prostate Cancer

Steven Finkelstein, MD, FACRO, discusses PSMA-PET imaging practices for patients experiencing biochemical recurrence.

Experts on prostate cancer offer clinical insights on identifying the appropriate patients for PSMA-PET imaging.

The panel discusses data on the accuracy of MRI-targeted or fusion-based biopsy procedures compared with systemic biopsy or MRI alone.

Firas F. Abdollah, MD, provides insights on how MRI- or fusion-guided technologies are used with transrectal and transperineal biopsy procedures and how they improve traditional biopsy procedures.

Data from a phase 1 study of KPG-121 were also recently presented at the 2024 ASCO Annual Meeting.

“We hope that the survey can be helpful in practice to actually assess and give advice to some of these partners of patients, in addition to the questionnaires that we use for the patients themselves,” says Stacy Loeb, MD, MSc.

"The main finding from this network meta-analysis is the ranking of the 4 treatment approaches that we considered," says Scott Morgan, MD, MSc, FRCPC.

The study reported a median rPFS of 8.8 months among 23 adult patients with previously treated, progressive mCRPC.

The change was made following the submission of a real-world evidence study showing that 5- to 10-year overall survival following robot-assisted radical prostatectomy was comparable to that of non-robotic radical prostatectomy.

"We hope this study encourages a national acceptance of active surveillance as an effective management strategy for prostate cancer,” says Daniel Lin, MD.

Focusing on prostate cancer diagnosis, the panel discusses transrectal and transperineal biopsies and limitations associated with them.

The panel discusses the role of PSMA-PET imaging in prostate cancer and highlights different PSMA agents.

A panel of experts on prostate cancer introduce themselves and begin the discussion with clinical insights on diagnostic practices and the importance of biopsy and imaging in guiding treatment decisions.

A panel of experts on prostate cancer provide an overview of conventional imaging modalities that have been used in the initial staging and management of prostate cancer and discuss the role of PSMA-PET imaging.

The IND acceptance will initiate the launch of a phase 1 trial to evaluate the safety, tolerability, and preliminary anti-tumor activity of 225Ac-FL-020 in patients with mCRPC.

"I think [these are] important data to [give to] your patients," says Laura Bukavina, MD, MPH.

"A unique aspect of AUA guidelines is the robust methodological review," says Todd M. Morgan, MD.

“I think ultimately, when we think about when do we deliver MDRT and to whom, it comes down to a goals of care discussion,” says Angela Jia, MD, PhD.

"Our first question is, in patients who were on the GLP1R agonists for a prolonged period of time, were those patients at increased or decreased risk of developing the most common GU malignancies?" says Laura Bukavina, MD, MPH.

"Since the phase 2 data of the combination therapy of LAE002 (afuresertib) plus LAE001 demonstrated encouraging anti-tumor activity and safety profile in patients with mCRPC, a following phase 3 pivotal trial design has been discussed with the US FDA and the approval for the protocol has been received this month," said Yong Yue, MD, PhD.

“Cancer is a journey which is very emotional as much as it is physical. And not only for the patients, but it is also for their caregivers, whoever that person is,” say Joy Maulik, CRNP.

"When thinking about living with prostate cancer, this is really a couples' disease, and partners' unmet needs should be part of the conversation," says Stacy Loeb, MD.

Preliminary results from the CUPID study were based on data from 11 evaluable patients with advanced prostate cancer.

"We were deeply impressed by Galen's performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely,” says Junya Fukuoka, MD, PhD.

"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.

"225Ac-PSMA-Trillium is a novel approach, which could provide a new treatment to address this unmet need in mCRPC,” says Fred Saad, MD, FRCS.

"One of the main summaries/focuses of this discussion was, how do we create action to improve screening, and what that actually means," says Samuel L. Washington III, MD, MAS.

In this interview, Mary-Ellen Taplin, MD, discusses disparities in prostate cancer care and a unique initiative aiming to alleviate those disparities.

"The biggest take home point is that patients with node-positive disease at the time of radical prostatectomy are a heterogeneous group of patients," says Daniel A. Triner, MD, PhD.

The Contouring Assistant now marks Profound Medical’s second FDA-cleared TULSA-AI module.